EF Hutton Assumes Jasper Therapeutics at Buy, Announces Price Target of $6.85
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Michael King assumes coverage of Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces a price target of $6.85.
May 25, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics (NASDAQ:JSPR) receives a Buy rating from EF Hutton analyst Michael King, with a price target of $6.85.
The Buy rating and price target announcement by EF Hutton analyst Michael King is likely to have a positive short-term impact on JSPR's stock price. Investors may view this as a sign of confidence in the company's potential, leading to increased buying pressure and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100